News

Researchers have identified distinct genetic changes tied to the severity of idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Data showed that the expression (activity) of the ABCA3 gene was lower in IPAH patients, while that of the SMAD9 gene was increased in CTEPH, particularly…

The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Dubbed SERANATA, the study aims to enroll about 480 people with PH-ILD, ages 18 to 80. No…

Treprostinil may help manage pulmonary hypertension (PH) in children who’ve undergone Fontan surgery for congenital heart defects, according to a study in China. The treatment was associated with lower mean pulmonary arterial pressure (PAP) and improved oxygenation — oxygen delivery to tissues. The therapy was well tolerated, with no…

The investigational treatment TX45 may help improve heart function and circulatory health in people with pulmonary hypertension and heart failure with reduced ejection fraction (PH‑HFrEF). That’s according to new early clinical trial data announced by developer Tectonic Therapeutic, which tested a single intravenous (into-the-vein) dose of the therapy…

The advocacy organization Phaware has launched a new mobile app to help people living with pulmonary hypertension (PH) better manage their condition. Called Heart Works – phaware, the app is available on iPhone, Apple Watch, and Android devices — launching just in time for…

The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for Merck‘s Winrevair (sotatercept-csrk) that more specifically details how the pulmonary arterial hypertension (PAH) therapy reduces the risk of serious complications. Winrevair was approved by the FDA last year to improve…

From 1990 to 2021, cases of pulmonary arterial hypertension (PAH) increased worldwide among older adults, mainly due to growing aging populations. Elderly women were found to face the highest risk of death, according to data from the Global Burden of Disease Study. “Our findings provided a novel global perspective…

An eight-week exercise program using kettlebells — a weight tool consisting of a heavy cast-iron ball and handle — led to gains in physical performance, breathing efficiency, and muscle strength in people with pulmonary arterial hypertension (PAH), according to a new study from Turkey. Kettlebell training also improved quality…

Treatment with anticoagulants, also known as blood thinners, does not extend survival in people with pulmonary arterial hypertension (PAH), according to a large French study. These findings were supported by an additional pooled analysis of published studies involving more than 2,000 PAH patients, researchers found. “From the most rigorous…

Global death rates and levels of disability among newborns with pulmonary arterial hypertension (PAH) have declined since 1990, while the incidence of new cases has remained stable, according to a 30-year analysis. Still, mortality and disability rates are disproportionately higher in countries with low economic status, “underscoring the critical…

Researchers used computer-based modeling to develop a measure, called pulmonary vascular compromise (PVC), which estimates the reduced function of the pulmonary blood vessels in children with pulmonary arterial hypertension (PAH), according to a study. Supported by clinical data, a higher PVC, meaning a loss of the pulmonary vasculature, was…

Long-term treatment with Tyvaso DPI safely and effectively leads to increases in exercise capacity in adults with pulmonary arterial hypertension (PAH). Tyvaso DPI is a dry powder, inhaled form of treprostinil. Patient satisfaction was also improved with Tyvaso DPI compared with Tyvaso, which is a nebulized, inhaled formulation…